TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Radiopharm Theranostics Limited ( (AU:RAD) ) has issued an announcement.
Radiopharm Theranostics Limited has released a presentation for its Annual General Meeting, highlighting key considerations for investors. The presentation emphasizes that it does not constitute personal investment advice and outlines the potential risks and uncertainties associated with the company’s clinical trials and regulatory approvals. Stakeholders are advised to seek professional investment advice and to be aware of the legal restrictions on the distribution of the presentation, particularly concerning securities laws in the United States.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on NASDAQ and ASX under the ticker symbols RADX and RAD, respectively.
Average Trading Volume: 6,617,441
Technical Sentiment Signal: Sell
Current Market Cap: A$63.96M
See more insights into RAD stock on TipRanks’ Stock Analysis page.